Biosimilar Development solution center
-
Will It Be Biologics Business As Usual In 2021, Or Will Biosimilars Mean Business?
1/20/2021
In this fourth installment of the Editorial Board 2021 Outlook, it's clear that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing.
-
The Top 5 Biosimilar Developments Of 2020
12/30/2020
Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.
-
The Second Wave Of Biosimilars: New Scenarios, New Rules
12/15/2020
The arrival of what we could call the first “bio patent cliff” has revealed important lessons that should be taken into consideration when selecting new candidates for the second and third waves.
-
Biosimilar Experts Reflect On 2020’s Greatest Biosimilar Achievements
12/9/2020
As the amazing members of the Biosimilar Development Editorial Board emphasize here, there is a lot to be thankful for in the biosimilar world. Check out the first of what will be a four-part series showcasing the editorial board’s thoughts on the past year and the year(s) ahead.
-
Accelerate Your Pipeline With CDMO Collaboration
12/1/2020
A CDMO can augment your capacity and expertise, refine your processes, and ultimately shorten your time to market. Explore best practices that make working with a CDMO as efficient as possible.
-
3 Expert Perspectives On Biosimilar Differentiation & Biobetter Development
11/18/2020
In part two of this two-part series, several experts from a DIA panel share additional insights around the types of differentiation biosimilar companies can pursue and its overall impact on product/device selection and the manufacturing process.
-
Biosimilar Or Biobetter? Perspectives On An Evolving Market
11/11/2020
A recent webinar from IQVIA on the biosimilar and “biobetter” landscape provided a great overview of the opportunities for differentiation and the outlook for biobetter development. In part one of this two-part article on differentiation, I’ll share some of my main takeaways from IQVIA’s webinar.
-
Will Biosimilar Manufacturers Pursue Lower-Revenue Products?
11/10/2020
Will biosimilar makers have any motivation to develop biosimilar competitors for biologics earning considerably less in U.S. sales than previous generations? Biosimilar Development decided to do a deeper dive into one of these products, which may represent a broader base of biologic agents beyond autoimmune and oncology agents.
-
IQVIA’s U.S. Biosimilar Report: Your Most Pressing Questions Answered
11/4/2020
In recent weeks, there have been several reports released on the current state of the U.S. biosimilar market — including IQVIA's "Biosimilars in the U.S. 2020-2024." Overall, there were a few data points from this report I thought were worth singling out and discussing a bit further.
-
Mapping The Development Of A Biosimilar Candidate: Analytical & Regulatory Decisions
10/27/2020
This article, the first in a two-part series, details the biosimilar development path to identify and evaluate critical quality attributes for both the candidate biosimilar and the reference product, along the regulatory timeline.